MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Other Non-current Assets
Long-term assets not reported separately.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Other non-current assets falls 98.9% from a year ago
Other non-current assets stood at $36K at the end of Q1 FY2026, down 98.9% from a year earlier and down 39.0% from the prior quarter. Over 3 fiscal years it compounded at -36.8% a year.
Context
- Other non-current assets amounted to 0.0% of total assets at the end of Q1 FY2026, down 3.1 pp from a year earlier.
- Other non-current assets increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current assets keeps falling in the next quarterly balance sheet after a -98.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 59K USD
- Year-over-year change
- -98.1%
- 3-year CAGR
- -36.8%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 59K | -98.1% |
| FY2024 | 2024-12-31 | 3.17M | +1253.0% |
| FY2023 | 2023-12-31 | 234K | +0.0% |
| FY2022 | 2022-12-31 | 234K | — |
Other Non-current Assets vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's Mar 2026 other non-current assets of $36K is the 9th highest of the 11 companies compared; the peer median is $947.5K.
- Its year-over-year change of -98.9% is the 7th highest of 8, against a peer median of +125.2%.
- Other non-current assets amounts to 0.0% of total assets for MPLT, versus a peer median of 0.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $487.03M | — | — | 0.5% | |
| Mar 2026 | $12.01M | +521.5% | — | 5.3% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $2.61M | +126.6% | +37.6% | 0.2% |
| Mar 2026 | $2.46M | +125.2% | — | 0.9% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $1.06M | +400.9% | — | 0.2% |
| Mar 2026 | $838K | +47.3% | +83.2% | 0.3% | |
| Mar 2026 | $143K | -98.7% | +12.2% | 0.1% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $53K | — | -76.6% | 0.0% |
| Mar 2026 | $36K | -98.9% | -36.8% | 0.0% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $0 | -100.0% | — | 0.0% |
| Dec 2025 | $0 | — | — | 0.0% | |
| Peer median (excluding MPLT) | $947.5K | +125.2% | +24.9% | 0.2% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.